Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 320 participants.

Also called NCT01646320

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 320 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01646320
  • EudraCT 2011-006324-20
Other papers using this trial's data
  • Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes Diabetes care, 2015-11 DOI, PubMed 26246458

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Czechia, Mexico, Poland, Puerto Rico, Romania, Russia, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01646320. Randomized; triple masking; primary purpose treatment. Start 2012-09 (registry gives no type); primary completion 2014-08 (actual). Results posted on 2016-04-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Placebo matching with Dapagliflozin
Intervention (Drug)
Saxagliptin
Intervention (Drug)
Metformin immediate release (IR)
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct01646320
Content hash
b162d986258e64f313f8e07d621e92bb8a850a61e23684c756e5d5a3d6350bd3